Details for Patent: 10,703,763
✉ Email this page to a colleague
Which drugs does patent 10,703,763 protect, and when does it expire?
Patent 10,703,763 protects XIFAXAN and is included in one NDA.
This patent has thirty-four patent family members in twenty-six countries.
Summary for Patent: 10,703,763
Title: | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Abstract: | Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. |
Inventor(s): | Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara, IT), Barbanti; Maria (Bologna, IT), Braga; Dario (Bologna, IT) |
Assignee: | ALFASIGMA S.P.A. (Bologna, IT) |
Application Number: | 16/291,900 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,703,763
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. | ⤷ Try a Trial | ||||
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Try a Trial | ||||
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS | ⤷ Try a Trial | ||||
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-002 | Mar 24, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,703,763
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
05004695 | Mar 3, 2005 |
International Family Members for US Patent 10,703,763
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2006222312 | ⤷ Try a Trial | |||
Brazil | PI0608073 | ⤷ Try a Trial | |||
Canada | 2594789 | ⤷ Try a Trial | |||
China | 1900077 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |